Table 7.
Overall survival based on subtype and systemic therapies in patients aged 50-69 years (ESG)
| ESG | 3-year OS (%) | 5-year OS (%) | 6-year OS (%) | 7-year OS (%) |
|---|---|---|---|---|
| Luminal A (n = 1111) | ||||
| ET (n = 700 → 17 events) | 99.4 | 98.4 | 98.0 | 95.6 |
| CHT + ET (n = 296 → 24 events) | 99.0 | 96.4 | 94.9 | 93.1 |
| CHT (n = 25 → 2 events) | 92.0 | 92.0 | 92.0 | 92.0 |
| Other (n = 90 → 9 events) | 92.2 | 89.4 | 85.4 | 78.8 |
| Luminal B (n = 504) | ||||
| ET (n = 205 → 17 events) | 97.5 | 94.1 | 94.1 | 92.1 |
| CHT + ET (n = 240 → 23 events) | 97.3 | 92.2 | 90.0 | 88.2 |
| CHT (n = 26 → 5 events) | 81.7 | 81.7 | 81.7 | 81.7 |
| Other (n = 33 → 6 events) | 74.2 | 74.2 | 74.2 | 74.2 |
| HER2-like (n = 376) | ||||
| ET + Trastuzumab (n = 7 → 0 event) | – | – | – | – |
| ET (n = 68 → 6 events) | 98.5 | 93.2 | 88.8 | 88.8 |
| CHT + ET (n = 70 → 9 events) | 100 | 95.0 | 89.7 | 87.8 |
| CHT + ET + Trastuzumab (n = 104 → 4 events) | 97.6 | 96.0 | 96.0 | 92.2 |
| CHT + Trastuzumab (n = 60 → 2 events) | 98.2 | 98.2 | 93.9 | 93.9 |
| CHT (n = 37 → 10 events) | 82.3 | 75.4 | 75.4 | 75.4 |
| Other (n = 30 → 3 events) | 93.1 | 86.9 | 86.9 | 86.9 |
| Basal-like (n = 180) | ||||
| ET (n = 1 → 0 event) | – | – | – | – |
| CHT + ET (n = 8 → 1 event) | 87.5 | 87.5 | 87.5 | 87.5 |
| CHT (n = 140 → 16 events) | 92.3 | 87.3 | 87.3 | 85.5 |
| Other (n = 31 → 10 events) | 66.9 | 66.9 | 66.9 | 66.9 |